Literature DB >> 8097493

Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis.

P L Fidel1, M E Lynch, J D Sobel.   

Abstract

Women with recurrent vulvovaginal candidiasis often demonstrate a down-regulation of cell-mediated immunity (CMI) to Candida albicans detected by a lack of cutaneous delayed-type hypersensitivity (DTH) to Candida antigens. However, the role of systemic CMI as a host defense mechanism against recurrent vulvovaginal candidiasis is not well understood, in part because of the lack of a well-defined murine model of vaginal candidiasis. The present study was undertaken to determine: (i) whether soluble Candida culture filtrate antigens (CaCF) could be used to induce and detect Candida-specific CMI in mice and (ii) whether these antigens would be useful in detecting systemic CMI in mice given an experimental Candida vaginal infection. To this end, mice were immunized subcutaneously with CaCF in complete Freund's adjuvant, and within 7 days they developed Candida-specific DTH reactivity detected by footpad swelling (increase in footpad thickness, 0.36 mm) 24 h after footpad challenge with CaCF. Adoptive transfer studies showed that the DTH responsiveness was elicited by CD4+ DTH T cells. In mice given a vaginal inoculum of C. albicans blastoconidia (5 x 10(5)), footpad challenge with CaCF resulted in positive DTH responses (0.24 mm) as early as 1 week, responses similar to immunization in 2 to 3 weeks (0.33 mm), and sustained low levels of DTH reactivity (0.15 mm) through 10 weeks of vaginal infection. Vaginal lavage cultures revealed that peak vaginal Candida burden occurred 1 week post-vaginal inoculation (10(5) CFU) and declined 16-fold by week 10. These results provide evidence that Candida-specific systemic CMI is generated and can be detected longitudinally in mice with Candida vaginitis by a multiantigen preparation of Candida organisms which both initiates and detects Candida-specific CMI.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097493      PMCID: PMC280793          DOI: 10.1128/iai.61.5.1990-1995.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Candidal vaginitis.

Authors:  R Hurley
Journal:  Proc R Soc Med       Date:  1977

2.  Immunological aspects of candidal vaginitis.

Authors:  J R Hobbs; D Brigden; F Davidson; M Kahan; J K Oates
Journal:  Proc R Soc Med       Date:  1977

3.  Gastrointestinal candidiasis in a murine model of severe combined immunodeficiency syndrome.

Authors:  R Narayanan; W A Joyce; R A Greenfield
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

4.  Chronic mucocutaneous candidiasis, deficiency of delayed hypersensitivity, and selective local antibody defect.

Authors:  R A Chilgren; P G Quie; H J Meuwissen; R Hong
Journal:  Lancet       Date:  1967-09-30       Impact factor: 79.321

5.  Defective cellular immunity associated with chronic mucocutaneous moniliasis and recurrent staphylococcal botryomycosis: immunological reconstitution by allogeneic bone marrow.

Authors:  R H Buckley; Z J Lucas; B G Hattler; C M Zmijewski; D B Amos
Journal:  Clin Exp Immunol       Date:  1968-02       Impact factor: 4.330

6.  Immunological observations in chronic mucocutaneous candidiasis.

Authors:  L Canales; R O Middlemas; J M Louro; M A South
Journal:  Lancet       Date:  1969-09-13       Impact factor: 79.321

7.  Chronic mucocutaneous moniliasis with impaired delayed hypersensitivity.

Authors:  C H Kirkpatrick; J W Chandler; R N Schimke
Journal:  Clin Exp Immunol       Date:  1970-03       Impact factor: 4.330

8.  Mucocutaneous candidiasis, anergy and a plasma inhibitor of cellular immunity: reversal after amphotericin B therapy.

Authors:  P Y Paterson; R Semo; G Blumenschein; J Swelstad
Journal:  Clin Exp Immunol       Date:  1971-11       Impact factor: 4.330

9.  Cellular immunity of patients with recurrent or refractory vulvovaginal moniliasis.

Authors:  I W Fong; P McCleary; S Read
Journal:  Am J Obstet Gynecol       Date:  1992-03       Impact factor: 8.661

10.  Role of CD4+ lymphocytes in resistance to mucosal candidiasis.

Authors:  M T Cantorna; E Balish
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

View more
  51 in total

1.  Evidence for a unique expression of CD4 on murine vaginal CD4+ cells.

Authors:  F L Wormley; M Scott; W Luo; M Baker; J Chaiban; P L Fidel
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

2.  A new model of vaginal infection by Candida albicans in rats.

Authors:  Márcia A Carrara; Lucélia Donatti; Edílson Damke; Terezinha I E Svidizinski; Márcia E L Consolaro; Márcia R Batista
Journal:  Mycopathologia       Date:  2010-06-09       Impact factor: 2.574

3.  Increased susceptibility of secretor factor gene Fut2-null mice to experimental vaginal candidiasis.

Authors:  Elizabeth A Hurd; Steven E Domino
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

4.  Cell adhesion molecule and lymphocyte activation marker expression during experimental vaginal candidiasis.

Authors:  F L Wormley; J Chaiban; P L Fidel
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

5.  Effects of reproductive hormones on experimental vaginal candidiasis.

Authors:  P L Fidel; J Cutright; C Steele
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

6.  Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

7.  Role of calcineurin in stress resistance, morphogenesis, and virulence of a Candida albicans wild-type strain.

Authors:  Teresa Bader; Klaus Schröppel; Stefan Bentink; Nina Agabian; Gerwald Köhler; Joachim Morschhäuser
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

8.  Candida albicans VPS4 contributes differentially to epithelial and mucosal pathogenesis.

Authors:  Hallie S Rane; Sarah Hardison; Claudia Botelho; Stella M Bernardo; Floyd Wormley; Samuel A Lee
Journal:  Virulence       Date:  2014-10-31       Impact factor: 5.882

9.  A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.

Authors:  Y Han; R P Morrison; J E Cutler
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

10.  Candida-specific antibodies during experimental vaginal candidiasis in mice.

Authors:  Karen L Wozniak; Floyd L Wormley; Paul L Fidel
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.